Development Trend of Medicinal Chemistry

The progress of medicinal chemistry and a large number of new drugs listed in the late 20th century, mainly summarized as two reasons: 1) Life sciences, such as structural biology, molecular biology, molecular genetics, genetics and biotechnology, to provide theoretical basis and technical support for the discovery of new drugs; 2) the rapid development of scientific information such as the establishment of bioinformatics, the development of biochips, the application of various information kiosks and information technology, can easily retrieve and search the required literature and the research level and efficiency greatly improved.

In order to strive for the international market, pharmaceutical companies invested a lot of money for new drug research and development; new varieties of drugs continue to promote the rapid development of the pharmaceutical industry.

We will usher in the new century of knowledge economy in the near future. Knowledge innovation, technological innovation, scientific and technological progress and economic development will be the main task facing life science and information science will be increasingly developed to become an active area of the next century, which for disease prevention and treatment, new drug research provides an important foundation.

Medicinal chemistry, biology and biotechnology connected closely is still the future development trend.

Medicilon’s chemistry department possesses advanced synthetic medicinal chemistry skills and an excellent record-tracking system to progress programs and generate preclinical candidates. We can rapidly transform your drug discovery program from hit screening to SAR-driven medicinal chemistry in an efficient and cost effective manner. We use state-of-the-art parallel synthesis and purification technology to prepare high-quality compound libraries. Our chemists have extensive experiences in working with clients on hit to lead and lead optimization for candidate’s programs, and in converting medicinal synthetic routes of compounds into processes that make multi-kilogram quantities to support animal studies within a restricted time frame.

Medicinal Chemistry

We utilize medicinal chemistry efficiently and cost-effectively to progress our client’s drug discovery projects to candidate nomination, preclinical development, and IND.

> Hit to lead and/or lead optimization
> Rational Drug Design
> Computer Aided Drug Design (CADD)
> Structure Activity Relationship (SAR) Campaign
> Final Lead Optimization and Candidate Nomination
> Process Development of Preclinical Candidate

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%.

Well-designed and well-validated analytical methodology is critical to data integrity and central to our approach. We work closely with clients to ensure that our methodology will yield accurate results. Meanwhile, our precise quality systems ensure that all the facilities, equipment, methods, practices, records, and controls are tightly compliant with our regulations, study protocols, and standard operating procedures.

Contact Us

Email : marketing@medicilon.com

Tel : +44 1223 981 792 (Europe)

+82 (0)70-8269-5849 (South Korea)

08044216898 (Japan)

+86 021 58591500 (China)

Website: https://www.medicilon.com

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客